One of the goals of the Hatch-Waxman framework is to provide a clear pathway for generic drug entry. In recent years, some generic manufacturers have expressed concerns that Hatch-Waxman litigation is only the beginning as brands seek to assert patents on the same product through waves of litigation following the initial dispute. This panel will examine the need for balance between protecting patent rights and generic entry and the impact of serial litigation on Hatch-Waxman cases.

Key Topics:

• Examining case study examples of waves of litigation on the same drug product
  • Assessing whether serial litigation could have been avoided
• Brand perspectives on protecting IP on patents not asserted in the initial Hatch-Waxman dispute
• Developing case management strategies and budgets in anticipation of further litigation
• Deciding when to launch a generic product against the risk of potential damages

Speakers:
David Abramowitz, Partner, Buchanan Ingersoll & Rooney, PC
Alison Hanstead, Partner, White & Case
Kurt Mathas, Partner, Winston & Strawn
Howard Suh, Partner, Fox Rothschild

Please note there is a cost to attend.